Antibiotic resistance, heteroresistance, and eradication success of Helicobacter pylori infection in children.
Child
Humans
Helicobacter Infections
/ epidemiology
Helicobacter pylori
Anti-Bacterial Agents
/ pharmacology
Clarithromycin
/ therapeutic use
Amoxicillin
/ pharmacology
Metronidazole
/ pharmacology
Levofloxacin
/ pharmacology
Drug Resistance, Bacterial
Tetracycline
/ therapeutic use
Drug Therapy, Combination
Helicobacter pylori
antimicrobial resistance
antimicrobial susceptibility
children
heteroresistance
Journal
Helicobacter
ISSN: 1523-5378
Titre abrégé: Helicobacter
Pays: England
ID NLM: 9605411
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
19
06
2023
received:
30
01
2023
accepted:
20
06
2023
medline:
6
9
2023
pubmed:
4
7
2023
entrez:
4
7
2023
Statut:
ppublish
Résumé
Antibiotic resistance is a well-known factor of Helicobacter pylori eradication failure. Heteroresistance indicates the coexistence of resistant and susceptible strains and might lead to underestimating antimicrobial resistance. This study aims to evaluate the susceptibility profile, the frequency of heteroresistance of H. pylori strains, and their effect on eradication success in a pediatric population. Children aged 2-17 years who underwent an upper gastrointestinal endoscopy from 2011 to 2019 with positive H. pylori status were included. Susceptibility was measured by disk diffusion and E-test. The difference in susceptibility profiles between isolates from the antrum and the corpus was used to detect heteroresistance. For those who received eradication treatment, we evaluated eradication rate and factors affecting treatment success. Inclusion criteria were met by 565 children. Strains susceptible to all antibiotics were detected in 64.2%. Primary resistance rates for clarithromycin (CLA), metronidazole (MET), levofloxacin (LEV), tetracyclin (TET), and amoxicillin (AMO) were 11%, 22.9%, 6.9%, 0.4%, and 0% and secondary resistance rates were 20.4%, 29.4%, 9.3%, 0%, and 0%. Heteroresistance was present in untreated children in 2%, 7.1%, 0.7%, 0.7%, and 0% for CLA, MET, LEV, TET, and AMO. First-line eradication rates were 78.5% in intention-to-treat (ITT), 88.3% in full-analysis-set (FAS), and 94.1% in per-protocol (PP). Factors affecting eradication success were the duration of treatment when the triple-tailored treatment was used, the number of daily doses of amoxicillin administered, and the patient's adherence to treatment. This study shows the presence of relatively low primary resistance rates for H. pylori isolates but demonstrates the presence of heteroresistance in our population. Routine biopsies from the antrum and corpus must be considered for susceptibility testing to allow tailored treatments and increase eradication rates. Treatment success is affected by treatment choice, correct dosing of medications, and adherence. All these factors should be considered when evaluating the efficacy of an eradication regimen.
Sections du résumé
BACKGROUND
BACKGROUND
Antibiotic resistance is a well-known factor of Helicobacter pylori eradication failure. Heteroresistance indicates the coexistence of resistant and susceptible strains and might lead to underestimating antimicrobial resistance. This study aims to evaluate the susceptibility profile, the frequency of heteroresistance of H. pylori strains, and their effect on eradication success in a pediatric population.
MATERIALS AND METHODS
METHODS
Children aged 2-17 years who underwent an upper gastrointestinal endoscopy from 2011 to 2019 with positive H. pylori status were included. Susceptibility was measured by disk diffusion and E-test. The difference in susceptibility profiles between isolates from the antrum and the corpus was used to detect heteroresistance. For those who received eradication treatment, we evaluated eradication rate and factors affecting treatment success.
RESULTS
RESULTS
Inclusion criteria were met by 565 children. Strains susceptible to all antibiotics were detected in 64.2%. Primary resistance rates for clarithromycin (CLA), metronidazole (MET), levofloxacin (LEV), tetracyclin (TET), and amoxicillin (AMO) were 11%, 22.9%, 6.9%, 0.4%, and 0% and secondary resistance rates were 20.4%, 29.4%, 9.3%, 0%, and 0%. Heteroresistance was present in untreated children in 2%, 7.1%, 0.7%, 0.7%, and 0% for CLA, MET, LEV, TET, and AMO. First-line eradication rates were 78.5% in intention-to-treat (ITT), 88.3% in full-analysis-set (FAS), and 94.1% in per-protocol (PP). Factors affecting eradication success were the duration of treatment when the triple-tailored treatment was used, the number of daily doses of amoxicillin administered, and the patient's adherence to treatment.
CONCLUSIONS
CONCLUSIONS
This study shows the presence of relatively low primary resistance rates for H. pylori isolates but demonstrates the presence of heteroresistance in our population. Routine biopsies from the antrum and corpus must be considered for susceptibility testing to allow tailored treatments and increase eradication rates. Treatment success is affected by treatment choice, correct dosing of medications, and adherence. All these factors should be considered when evaluating the efficacy of an eradication regimen.
Substances chimiques
Anti-Bacterial Agents
0
Clarithromycin
H1250JIK0A
Amoxicillin
804826J2HU
Metronidazole
140QMO216E
Levofloxacin
6GNT3Y5LMF
Tetracycline
F8VB5M810T
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13006Informations de copyright
© 2023 John Wiley & Sons Ltd.
Références
Jones NL, Koletzko S, Goodman K, Bontems P, Cadranel S, Casswall T. Joint ESPGHAN/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr. 2017;64:991-1003.
Hooi JKY, Lai WY, Ng WK, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology. 2017;153(2):420-429.
Le Thi TG, Werkstetter K, Kotilea K, et al. Helicobacter pylori special interest group of ESPGHAN. Management of Helicobacter pylori infection in pediatric patients in Europe: results from the EuroPedHp registry. Infection. 2022. Published online 3 November 2022.
Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;155(5):1372-1382.e17.
Kotilea K, Mekhael J, Salame A, et al. Eradication rate of Helicobacter pylori infection is directly influenced by adherence to therapy in children. Helicobacter. 2017;22(4).
Farzi N, Behzad C, Hasani Z, Alebouyeh M, Zojaji H, Zali MR. Characterization of clarithromycin heteroresistance among Helicobacter pylori strains isolated from the antrum and corpus of the stomach. Folia Microbiol. 2019;64(2):143-151.
Mascellino MT, Porowska B, De Angelis M, Oliva A. Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection. Drug Des Devel Ther. 2017;11:2209-2220.
Matteo MJ, Pérez CV, Domingo MR, Olmos M, Sanchez C, Catalano M. DNA sequence analysis of rdxA and frxA from paired metronidazole-sensitive and -resistant Helicobacter pylori isolates obtained from patients with heteroresistance. Int J Antimicrob Agents. 2006;27(2):152-158.
Rizvanov AA, Haertlé T, Bogomolnaya L, Talebi Bezmin Abadi A. Helicobacter pylori and its antibiotic heteroresistance: a neglected issue in published guidelines. Front Microbiol. 2019;10:1796.
Tshibangu-Kabamba E, Yamaoka Y. Helicobacter pylori infection and antibiotic resistance-from biology to clinical implications. Nat Rev Gastroenterol Hepatol. 2021;18(9):613-629.
Kocsmár É, Kocsmár I, Buzás GM, et al. Helicobacter pylori heteroresistance to clarithromycin in adults-new data by in situ detection and improved concept. Helicobacter. 2019;25(1):e12670.
Miendje Deyi VY, Lare MS, Burette A, et al. Update of primary Helicobacter pylori resistance to antimicrobials in Brussels, Belgium. Diagn Microbiol Infect Dis. 2019;95(4):114875.
Glupczynski Y, Labbé M, Hansen W, Crokaert F, Yourassowsky E. Evaluation of the E test for quantitative antimicrobial susceptibility testing of Helicobacter pylori. J Clin Microbiol. 1991;29(9):2072-2075.
Miendje Deyi VY, Hammouti A, Fosseprez G, De Giorgi C, Debyttere A, Hallin M. Comparative evaluation of Helicobacter pylori susceptibility testing methods to optimize routine analysis. Microb Health Dis. 2021;3:e612.
Kotilea K, Cadranel S, Salame A, et al. Efficacy and safety of bismuth-based quadruple therapy for Helicobacter pylori eradication in children. Helicobacter. 2021;26(4):e12825.
Schwarzer A, Urruzuno P, Iwańczak B, et al. New effective treatment regimen for children infected with a double-resistant Helicobacter pylori strain. J Pediatr Gastroenterol Nutr. 2011;52(4):424-428.
Bontems P, Kalach N, Oderda G, et al. Sequential therapy vs. tailored triple therapies for Helicobacter pylori infection in children: a prospective, open-label, multi-center study. J Pediatr Gastroenterol Nutr. 2011;53(6):646-650.
Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377-381.
Kori M, Le Thi TG, Werkstetter K, et al. Helicobacter pylori infection in pediatric patients living in Europe: Results of the EuroPedHP registry 2013-2016. J Pediatr Gastroenterol Nutr. 2020;71(4):476-483.
Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318-327.
Miendje Deyi VY, Bontems P, Vanderpas J, et al. Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium. J Clin Microbiol. 2011;49(6):2200-2209.
Miendje Deyi VY, Ntounda R, Louis H, et al. Primary Helicobacter pylori resistance to antimicrobials in the Brussels area in 2021. Diagn Microbiol Infect Dis. 2023 Feb;105(2):115855. doi:10.1016/j.diagmicrobio.2022.115855
Kori MD, Yahav J, Berdinstein R, Shmuely H. Primary and secondary antibiotic resistance of Helicobacter pylori in Israeli children and adolescents. Isr Med Assoc J. 2017;19:747-750.
Lopo I, Libânio D, Pita I, Dinis-Ribeiro M, Pimentel-Nunes P. Helicobacter pylori antibiotic resistance in Portugal: systematic review and meta-analysis. Helicobacter. 2018;23(4):e12493.
Gościniak G, Biernat M, Bińkowska A, Kus A, Iwańczak B. Frequency of infection with Helicobacter pylori isolates of different antimicrobial profiles in children and adolescents: A preliminary study. Adv Clin Exp Med. 2017;26(2):263-268.
Bontems P, Devaster J-M, Corvaglia L, et al. Twelve year observation of primary and secondary antibiotic-resistant Helicobacter pylori strains in children. Pediatr Infect Dis J. 2001;20(11):1033-1038.
Koushari E, Sadeghifard N, Khadiv A, et al. Heteroresistance to clarithromycin and metronidazole in patients with a Helicobacter pylori infection: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob. 2022;21(1):19.
Ben Mansour K, Fendri C, Battikh H, et al. Multiple and mixed Helicobacter pylori infections: comparison of two epidemiological situations in Tunisia and France. Infect Genet Evol. 2016;37:43-48.
Güven B, Gülerman F, Kaçmaz B. Helicobacter pylori resistance to clarithromycin and fluoroquinolones in a pediatric population in Turkey: a cross-sectional study. Helicobacter. 2019;24(3):e12581.
Marzio L, Cellini L, Amitrano M, et al. Helicobacter pylori isolates from proximal and distal stomach of patients never treated and already treated show genetic variability and discordant antibiotic resistance. Eur J Gastroenterol Hepatol. 2011;23:467-472.
Shah SC, Iyer PG, Moss SF. AGA clinical practice update on the management of refractory Helicobacter pylori infection: expert review. Gastroenterology. 2021;160(5):1831-1841. doi:10.1053/j.gastro.2020.11.059
Furuta T, Sugimoto M, Yamade M, et al. Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy. J Clin Pharmacol. 2014;54(3):258-266.